Hit-to-Lead: Hit Validation and Assessment

Author(s):  
Kirk E. Hevener ◽  
Russell Pesavento ◽  
JinHong Ren ◽  
Hyun Lee ◽  
Kiira Ratia ◽  
...  
Keyword(s):  
2009 ◽  
Vol 53 (4) ◽  
pp. 1528-1531 ◽  
Author(s):  
Françoise Banères-Roquet ◽  
Maxime Gualtieri ◽  
Philippe Villain-Guillot ◽  
Martine Pugnière ◽  
Jean-Paul Leonetti

ABSTRACT The pharmacologic effect of an antibiotic is directly related to its unbound concentration at the site of infection. Most commercial antibiotics have been selected in part for their low propensity to interact with serum proteins. These nonspecific interactions are classically evaluated by measuring the MIC in the presence of serum. As higher-throughput technologies tend to lose information, surface plasmon resonance (SPR) is emerging as an informative medium-throughput technology for hit validation. Here we show that SPR is a useful automatic tool for quantification of the interaction of model antibiotics with serum proteins and that it delivers precise real-time kinetic data on this critical parameter.


2017 ◽  
Vol 12 (9) ◽  
pp. 897-907 ◽  
Author(s):  
Christine C. Genick ◽  
S. Kirk Wright

2014 ◽  
Vol 19 (5) ◽  
pp. 707-714 ◽  
Author(s):  
Christine Clougherty Genick ◽  
Danielle Barlier ◽  
Dominique Monna ◽  
Reto Brunner ◽  
Céline Bé ◽  
...  

For approximately a decade, biophysical methods have been used to validate positive hits selected from high-throughput screening (HTS) campaigns with the goal to verify binding interactions using label-free assays. By applying label-free readouts, screen artifacts created by compound interference and fluorescence are discovered, enabling further characterization of the hits for their target specificity and selectivity. The use of several biophysical methods to extract this type of high-content information is required to prevent the promotion of false positives to the next level of hit validation and to select the best candidates for further chemical optimization. The typical technologies applied in this arena include dynamic light scattering, turbidometry, resonance waveguide, surface plasmon resonance, differential scanning fluorimetry, mass spectrometry, and others. Each technology can provide different types of information to enable the characterization of the binding interaction. Thus, these technologies can be incorporated in a hit-validation strategy not only according to the profile of chemical matter that is desired by the medicinal chemists, but also in a manner that is in agreement with the target protein’s amenability to the screening format. Here, we present the results of screening strategies using biophysics with the objective to evaluate the approaches, discuss the advantages and challenges, and summarize the benefits in reference to lead discovery. In summary, the biophysics screens presented here demonstrated various hit rates from a list of ~2000 preselected, IC50-validated hits from HTS (an IC50 is the inhibitor concentration at which 50% inhibition of activity is observed). There are several lessons learned from these biophysical screens, which will be discussed in this article.


2016 ◽  
Vol 18 (8) ◽  
pp. 444-455 ◽  
Author(s):  
Stephanie M. Myers ◽  
Ruth H. Bawn ◽  
Louise C. Bisset ◽  
Timothy J. Blackburn ◽  
Betty Cottyn ◽  
...  

2010 ◽  
Vol 10 (3) ◽  
pp. 368-382 ◽  
Author(s):  
Stephanie Ludewig ◽  
Markus Kossner ◽  
Markus Schiller ◽  
Knut Baumann ◽  
Tanja Schirmeister

2010 ◽  
Vol 15 (8) ◽  
pp. 978-989 ◽  
Author(s):  
Masakazu Kobayashi ◽  
Kim Retra ◽  
Francis Figaroa ◽  
Johan G. Hollander ◽  
Eiso Ab ◽  
...  

Fragment-based drug discovery (FBDD) has become a widely accepted tool that is complementary to high-throughput screening (HTS) in developing small-molecule inhibitors of pharmaceutical targets. Because a fragment campaign can only be as successful as the hit matter found, it is critical that the first stage of the process be optimized. Here the authors compare the 3 most commonly used methods for hit discovery in FBDD: high concentration screening (HCS), solution ligand-observed nuclear magnetic resonance (NMR), and surface plasmon resonance (SPR). They selected the commonly used saturation transfer difference (STD) NMR spectroscopy and the proprietary target immobilized NMR screening (TINS) as representative of the array of possible NMR methods. Using a target typical of FBDD campaigns, the authors find that HCS and TINS are the most sensitive to weak interactions. They also find a good correlation between TINS and STD for tighter binding ligands, but the ability of STD to detect ligands with affinity weaker than 1 mM KD is limited. Similarly, they find that SPR detection is most suited to ligands that bind with KD better than 1 mM. However, the good correlation between SPR and potency in a bioassay makes this a good method for hit validation and characterization studies.


2021 ◽  
Author(s):  
Chunlong Ma ◽  
Haozhou Tan ◽  
Juliana Choza ◽  
Yuying Wang ◽  
Jun Wang

SARS-CoV-2 main protease (Mpro) is one of the most extensive exploited drug targets for COVID-19. Structurally disparate compounds have been reported as Mpro inhibitors, raising the question of their target specificity. To elucidate the target specificity and the cellular target engagement of the claimed Mpro inhibitors, we systematically characterize their mechanism of action using the cell-free FRET assay, the thermal shift-binding assay, the cell lysate Protease-Glo luciferase assay, and the cell-based Flip-GFP assay. Collectively, our results have shown that majority of the Mpro inhibitors identified from drug repurposing including ebselen, carmofur, disulfiram, and shikonin are promiscuous cysteine inhibitors that are not specific to Mpro, while chloroquine, oxytetracycline, montelukast, candesartan, and dipyridamole do not inhibit Mpro in any of the assays tested. Overall, our study highlights the need of stringent hit validation at the early stage of drug discovery.


Sign in / Sign up

Export Citation Format

Share Document